艾日布林：脂肪肉瘤的一种有效治疗选择。 - Suppr

Suppr

超能文献

Eribulin: an effective therapeutic option in liposarcoma.

作者信息

Das Manjulika

出版信息

Lancet Oncol. 2017 Oct;18(10):e569. doi: 10.1016/S1470-2045(17)30675-7. Epub 2017 Sep 8.

DOI:10.1016/S1470-2045(17)30675-7

PMID:28890295

Abstract

摘要

相似文献

Eribulin: an effective therapeutic option in liposarcoma.

Lancet Oncol. 2017 Oct;18(10):e569. doi: 10.1016/S1470-2045(17)30675-7. Epub 2017 Sep 8.

Eribulin: rediscovering tubulin as an anticancer target.

Clin Cancer Res. 2009 Jun 15;15(12):3903-5. doi: 10.1158/1078-0432.CCR-09-1023. Epub 2009 Jun 9.

Eribulin mesylate (Halaven) for breast cancer.

Med Lett Drugs Ther. 2011 Apr 18;53(1362):30-1.

Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer.

Future Oncol. 2019 May;15(14):1641-1653. doi: 10.2217/fon-2018-0936. Epub 2019 Mar 20.

Dedifferentiated liposarcoma: when eribulin can make the difference.

Future Oncol. 2020 Jan;16(1s):21-24. doi: 10.2217/fon-2019-0598. Epub 2019 Dec 24.

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.

Lancet. 2016 Apr 16;387(10028):1629-37. doi: 10.1016/S0140-6736(15)01283-0. Epub 2016 Feb 10.

A case of eribulin-induced regression of liposarcoma of the left funiculus in a heavily pretreated patient.

Future Oncol. 2020 Jan;16(1s):33-38. doi: 10.2217/fon-2019-0600.

Eribulin Shows Promise in Advanced Sarcoma.

Cancer Discov. 2015 Jul;5(7):OF4. doi: 10.1158/2159-8290.CD-NB2015-085. Epub 2015 Jun 4.

FDA Approves Eribulin for Advanced Liposarcoma.

Cancer Discov. 2016 Mar;6(3):OF1. doi: 10.1158/2159-8290.CD-NB2016-011. Epub 2016 Feb 3.

In brief: Two Drugs for soft-tissue sarcoma.

Med Lett Drugs Ther. 2016 May 9;58(1494):e62.

引用本文的文献

The microtubule targeting agents eribulin and paclitaxel activate similar signaling pathways and induce cell death predominantly in a caspase-independent manner.

Cell Cycle. 2020 Feb;19(4):464-478. doi: 10.1080/15384101.2020.1716144. Epub 2020 Jan 20.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Eribulin: an effective therapeutic option in liposarcoma.

Lancet Oncol. 2017 Oct;18(10):e569. doi: 10.1016/S1470-2045(17)30675-7. Epub 2017 Sep 8.

Eribulin: rediscovering tubulin as an anticancer target.

Clin Cancer Res. 2009 Jun 15;15(12):3903-5. doi: 10.1158/1078-0432.CCR-09-1023. Epub 2009 Jun 9.

Eribulin mesylate (Halaven) for breast cancer.

Med Lett Drugs Ther. 2011 Apr 18;53(1362):30-1.

Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer.

Future Oncol. 2019 May;15(14):1641-1653. doi: 10.2217/fon-2018-0936. Epub 2019 Mar 20.

Dedifferentiated liposarcoma: when eribulin can make the difference.

Future Oncol. 2020 Jan;16(1s):21-24. doi: 10.2217/fon-2019-0598. Epub 2019 Dec 24.

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.

Lancet. 2016 Apr 16;387(10028):1629-37. doi: 10.1016/S0140-6736(15)01283-0. Epub 2016 Feb 10.

A case of eribulin-induced regression of liposarcoma of the left funiculus in a heavily pretreated patient.

Future Oncol. 2020 Jan;16(1s):33-38. doi: 10.2217/fon-2019-0600.

Eribulin Shows Promise in Advanced Sarcoma.

Cancer Discov. 2015 Jul;5(7):OF4. doi: 10.1158/2159-8290.CD-NB2015-085. Epub 2015 Jun 4.

FDA Approves Eribulin for Advanced Liposarcoma.

Cancer Discov. 2016 Mar;6(3):OF1. doi: 10.1158/2159-8290.CD-NB2016-011. Epub 2016 Feb 3.

In brief: Two Drugs for soft-tissue sarcoma.

Med Lett Drugs Ther. 2016 May 9;58(1494):e62.

引用本文的文献

The microtubule targeting agents eribulin and paclitaxel activate similar signaling pathways and induce cell death predominantly in a caspase-independent manner.

Cell Cycle. 2020 Feb;19(4):464-478. doi: 10.1080/15384101.2020.1716144. Epub 2020 Jan 20.